AGP Picks
View all

CML treatment market to hit $12.17 billion by 2030

Nov. 18, 2026
CML treatment market to hit $12.17 billion by 2030
By AI, Created 15:45 UTC, Nov 18, 2026, AGP -

The chronic myeloid leukemia treatment market is projected to grow from $9.23 billion in 2026 to $12.17 billion by 2030, driven by targeted therapies, precision oncology and broader use of combination treatments. North America held the largest share in 2025, while new report features include forecasting dashboards, TAM analysis and market hotspot graphics.

Why it matters: - The CML treatment market is expanding as more patients are diagnosed and more therapies reach the market. - The forecast points to steady demand for targeted medicines and long-term disease management through 2030. - The market outlook matters for drugmakers, oncology providers and investors watching blood-cancer treatment trends.

What happened: - The Business Research Company released its Chronic Myeloid Leukemia Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the global chronic myeloid leukemia treatment market will rise from $8.64 billion in 2025 to $9.23 billion in 2026. - The report projects the market will reach $12.17 billion by 2030, at a CAGR of 7.2%. - The release was issued from London on Nov. 18, 2026. - A free sample is available here. - The full report is available here.

The details: - Historical growth was driven by better blood-cancer diagnostics, wider availability of first-generation tyrosine kinase inhibitors, rising awareness of CML, more oncology treatment centers and improved survival outcomes. - Expected growth through 2030 is tied to new targeted therapies, more combination treatment approaches, precision oncology programs, stronger focus on patient adherence and higher oncology research spending. - Key trends include broader use of targeted therapy regimens, more next-generation TKIs, greater reliance on molecular diagnostics, personalized treatment protocols and longer-term disease management. - CML is a blood and bone marrow cancer marked by excessive growth of abnormal myeloid white blood cells. - Treatment aims to slow disease progression and prevent advancement to more severe stages. - The report says rising CML prevalence is a major market driver. - In 2025, North America held the largest share of the CML treatment market. - The analysis also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future-trend analysis, and updated graphics and tables.

Between the lines: - The report signals a market shifting from broad treatment access toward more precise, durable and personalized care. - North America’s lead suggests the region remains the center of commercial activity, while other regions may offer growth as diagnosis and treatment access expand. - The emphasis on molecular diagnostics and adherence shows the market is moving beyond drug sales toward better disease monitoring and patient management.

What's next: - Adoption of next-generation TKIs and combination regimens is likely to shape the next phase of market growth. - Oncology research spending and precision medicine programs could accelerate product development and market penetration. - Regional growth opportunities may widen outside North America as healthcare systems expand access to CML care.

The bottom line: - CML treatment is set for steady growth through 2030, with targeted therapies and precision oncology driving the market forward.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

LATAM News Online

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

LATAM News Online

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.